Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Medication adherence is one of the most salient predictors of patient outcomes in the era following development of effective treatment for HIV infection. Evolving strategies to improve adherence, specifically incentive interventions and real-time medication monitoring, have shown some success in limited studies. Further investigation into incentive interventions for HIV-infected adolescents with poor medication adherence is necessary.
PRIMARY OBJECTIVE:
SECONDARY OBJECTIVES:
Upon enrollment, participants will receive education and a real-time medication monitor. Participants will be followed monthly in the clinic and will be prescribed thirty-day supplies of medication. During weeks 1-4 participants will establish a baseline with the real-time medication monitor. During weeks 5-28, participants will receive remote incentives based on their level of medication adherence as measured by the real-time medication monitor. Additional lottery-style incentives will occur at regular follow-up visits. No incentives will be applied during weeks 29-48. Participants will complete the protocol at the week 48 visit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study Participants | All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Incentive intervention model | Behavioral | All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of dosages taken within 2 hours of prescribed time per month | Data collected by a real-time medication monitor that records pillbox opening times. | Monthly through week 48 |
| Pharmacy pill count | Pharmacy pill count data is collected at each participant encounter, approximately once per month. | Monthly from 6 months prior to study start through week 48 |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility - Accrual percentage | Number of people enrolled in study/number approached for enrollment. | End of study (week 48) |
| Feasibility - Drop out rate | Number of people ending protocol early/ total enrollment |
Not provided
Inclusion Criteria:
≥16 and ≤ 24 years old
Documented diagnosis of HIV
Adolescent is aware of his/her HIV diagnosis
Adolescent understands either written or spoken English.
Adolescent is willing and able to provide informed consent or assent.
Adolescent has access to a phone and the internet at the time of enrollment.
Adolescent meets the definition of inadequate ARV adherence, which is any of the following in the previous 12 months:
Exclusion Criteria:
Not provided
Not provided
Youth with HIV who meet eligibility criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ronald Dallas, PhD | St. Jude Children's Research Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | United States |
Not provided
| Label | URL |
|---|---|
| St. Jude Children's Research Hospital | View source |
| Clinical Trials Open at St. Jude | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D055118 | Medication Adherence |
| ID | Term |
|---|---|
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| End of study (week 48) |
| Feasibility - Participant reported device concerns | Problems with the Wisepill devices as spontaneously reported by participants or as assessed at routine follow-up. | End of study (week 48) |
| Feasibility - Device replacement rate | Number of devices requiring replacement due to loss/theft/breakage | End of study (week 48) |
| Feasibility - Contact failure rate | Number of failed attempts to contact participants/total number of contact attempts made | End of study (week 48) |
| Feasibility - Staff hours per week | Hours spent providing remote incentives | End of study (week 48) |
| Feasibility - Adverse effects of incentives | Unexpected risks/harms of providing incentives as self-reported by participants. | End of study (week 48) |
| Percentage of participants who are satisfied with the incentive intervention | To assess participant satisfaction with the incentive intervention model. Patient satisfaction, assessed by ACASI survey, will be summarized and tabulated for baseline (week 0) and follow-up (week 48) measurements. | Enrollment (week 0) and end of study (week 48) |
| Effect of incentives on missed appointment rate | Descriptive statistics of numbers of missed appointments such as mean, interquartile range and median, during each study phase will be computed and compared | Enrollment (week 0) and end of study (week 48) |
| Effect of incentives on STI rates | Descriptive statistics of numbers of STI rates such as mean, interquartile range and median, during each study phase will be computed and compared | Enrollment (week 0) and end of study (week 48) |
| Change in biological parameters | To measure the effect of the incentive intervention on HIV viral load and CD4+ count. HIV viral load and CD4+ count measured at week 0, 12, 24, 36 and 48 will be summarized and plotted by descriptive statistics, such as mean and standard deviation. Mixed effects models will be applied to explore the effect of the intervention on HIV viral load and CD4+ count. | At weeks 0, 12, 24, 36 and 48 |
| Overall cost of incentive intervention | To determine the overall and per patient cost of the incentive intervention model the accumulated overall and per patient cost till week 48 will be summarized and tabulated. | End of study (week 48) |
| Association between adherence measures | To describe associations between adherence measures: Wisepill data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report. Associations of Wisepill adherence rates with pill count and pick up rates will be described by Pearson or Spearman's correlation coefficients and intraclass correlation coefficients as appropriate. | End of study (week 48) |
| D001519 | Behavior |